info@marketresearchfuture.com   ūüďě  +1 (855) 661-4441(US)   ūüďě  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Hematocrit Test Market Research Report Information By Product (Analyzer, Hematocrit Test Meter), Indication (Anemia, Leukemia, Lymphoma, Congenital Heart Disease, Kidney Tumor), End-User (Hospital, Clinic, Diagnostic Center) ‚Äď Global Forecast Till 2030


ID: MRFR/LS/4105-HCR | 110 Pages | Author: Rahul Gotadki| June 2024

Global Hematocrit Test Market Overview


The hematocrit test market Size valued at USD 2.47 Billion in 2023. The hematocrit test market industry is projected to rise from USD 2.57 Billion in 2024 to USD 4.56 Billion by 2032, exhibiting a compound yearly growth rate (CAGR) of 8.3% during the forecast period (2024 - 2032). Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body.


Hematocrit Test Market


The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.


Hematocrit Test Market Trends


Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The hematocrit test market is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the hematocrit test market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the hematocrit test market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.


Hematocrit Test Market Segmentation


The hematocrit test market is segmented on the basis of product, indication, devices, and end-user.


Hematocrit Test Product Insights


On the basis of product, the hematocrit test market is segmented into the analyzer, hematocrit test meter, and others.


Hematocrit Test Indication Insights


On the basis of indication, the hematocrit test market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.


Hematocrit Test End-user Insights


On the basis of the end-user, the hematocrit test market is segmented into hospitals & clinics, diagnostic centers, and others.


Hematocrit Test Regional Analysis      


The hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases. 


North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases.


In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth.


The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth.


The Middle East & Africa hold the least share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services.  In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries.


Key Players in the Hematocrit Test Market 


Some of the key players in hematocrit test market are 



  • Abbott (U.S.)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Siemens AG (Germany)

  • Bio-Rad Laboratories, Inc. (U.S.)

  • Horiba, Ltd. (Japan)

  • Mindray Medical International Limited (China)

  • Boule Diagnostics AB (Sweden)

  • Beckman Coulter, Inc. (U.S.)

  • Nihon Kohden Corporation (Japan)

  • Sysmex Corporation (Japan)

  • others


Intended Audience



  • Medical Device Manufacturers

  • Medical Device Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors

Report Attribute/Metric Details
  Market Size   2032: USD 4.56 Billion
  CAGR   8.3% (2024-2032)
  Base Year   2023
  Forecast Period  2024-2032
  Historical Data   2022
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Indication, Devices, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers ·  Rising prevalence of chronic diseases ·  Changing lifestyle ·  Increasing demand for diagnostic devices for cardiovascular diseases


Frequently Asked Questions (FAQ) :

Hematocrit tests are used to measure the percentage of red blood cells in the body.

Hematocrit tests market is expected to exhibit a strong 8.3% CAGR over the forecast period from 2024 to 2032.

Growing awareness about hematological diseases is the major driver for the hematocrit test market.

The Americas dominate the Global Hematocrit Test Market, followed by Europe

Leading players in the hematocrit test market include Abbott, Siemens AG, and Beckman Coulter, among others.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.